Clinical trials: HBP
Hydrocephalus, NPH (Normal Pressure Hydrocephalus)
CERTAS Programmable Valve Registry
Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.
- Conditions
- Hydrocephalus, NPH (Normal Pressure Hydrocephalus), IIH - Idiopathic Intracranial Hypertension
- Trial name
- CERTAS (NCT04207229)
- Testing
- CODMAN CERTAS Programmable Valves
- Where
- 8 sites in Germany, Netherlands
- Volunteers
- 35 people
- Sponsor
- Integra LifeSciences Corporation
Hypertension
Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
This is a prospective, multicenter, feasibility study on the safety and efficacy of renal denervation in patients with resistant hypertension.
- Trial name
- EnligHTN-I (NCT01438229)
- Testing
- St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)
- Where
- 4 sites in Australia, Greece
- Volunteers
- 47 people
- Sponsor
- Abbott Medical Devices
Glaucoma Primary Open Angle
Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
The objective of this phase IV clinical multi-center trial will be to compare the efficacy and safety of Ganforti® versus Krytantek®, using a cross-over design during a six month period (including a one-month wash-in period) in…
- Trial name
- NCT01737853
- Testing
- Ganforti, Krytantek
- Where
- 4 sites in Mexico
- Volunteers
- 90 people
- Sponsor
- Allergan S.A. DE C.V..
Hypertension
Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)
The purpose of this study was to determine the safety of clevidipine for treating severely elevated blood pressure, defined as systolic (SBP) >180 mmHg and/or diastolic blood pressure (DBP) >115 mmHg assessed on 2 successive…
- Trial name
- VELOCITY (NCT00369837)
- Testing
- clevidipine
- Where
- 14 sites in United States
- Volunteers
- 131 people
- Sponsor
- The Medicines Company
Hypertension
Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers
A randomized, open-label, fed, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-385 in healthy volunteers
- Trial name
- NCT03748212
- Testing
- D935 Cap. 1T, CKD-385 Tab. 1T
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Primary Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose
Primary objective: The primary objective is to demonstrate the superiority of Monoprost® versus Lumigan® 0.01% and Lumigan® 0.03% Unit Dose in term of safety with respect to the assessment of conjunctival hyperaemia in the worse…
- Trial name
- NCT02017327
- Testing
- Monoprost, Lumigan 0.01%, Lumigan 0.03% Unit Dose
- Where
- France
- Volunteers
- 379 people
- Sponsor
- Laboratoires Thea
Ocular Hypertension
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
- Trial name
- NCT00332059
- Testing
- bimatoprost/timolol fixed combination
- Where
- 4 sites in United States, Austria and 2 more
- Volunteers
- 445 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension
This study will investigate the safety and efficacy of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) in patients with glaucoma or ocular hypertension who have elevated…
- Trial name
- NCT01216943
- Testing
- bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution
- Where
- India
- Volunteers
- 126 people
- Sponsor
- Allergan
Hypertension, Dyslipidemias
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers
This study is a randomized, open-label, fasted, single dose, crossover study to investigate the pharmacokinetic profiles and safety of CKD-333 in healthy volunteers.
- Trial name
- NCT04019743
- Testing
- CKD-330 16/10mg Tab. 1T and D086 Tab. 1T, CKD-333 16/10/40mg formulation 1 Tab. 1T, CKD-333 16/10/40mg formulation 2 Tab. 1T
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study
It is a national, retrospective , observational study in hypertensive patients treated for at least 8 weeks with the fixed dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg.
- Trial name
- NCT00909038
- Where
- 915 sites in France
- Volunteers
- 2,411 people
- Sponsor
- Boehringer Ingelheim
Hypertension
A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension
The purpose of this study is to evaluate the efficacy, safety and tolerability of long-term use (up to 18 weeks) of valsartan in children 6 months to 5 years old with hypertension.
- Trial name
- NCT00457626
- Testing
- Valsartan
- Where
- 36 sites in United States, Belgium and 8 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Intraocular Pressure
Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension
The objective of this clinical investigation is to determine the most effective drug concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical development of an appropriate dose with regard to…
- Trial name
- Voyager (NCT01223378)
- Testing
- BOL-303259-X, Latanoprost
- Where
- United States
- Volunteers
- 413 people
- Sponsor
- Bausch & Lomb Incorporated
Hypertension
A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT05362110)
- Testing
- HCP1803-3, RLD2002, HPP2003-3
- Where
- South Korea
- Volunteers
- 361 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Glaucoma, Ocular Hypertension
Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension
The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT00061503
- Testing
- Travoprost
- Where
- United States
- Sponsor
- Alcon Research
Hemorrhagic Stroke
Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)
Because of its pharmacokinetic characteristics, such as short half-life and its safety profile, esmolol hydrochloride is a beta blocker suitable for venous use in the form of continuous infusion.
- Trial name
- ETHICHS (NCT03743103)
- Testing
- Brevibloc, 10 Mg/mL Intravenous Solution, Nitroprusside, Sodium
- Where
- 7 sites in Brazil
- Volunteers
- 20 people
- Sponsor
- Cristália Produtos Químicos Farmacêuticos Ltda.
Hypertension, Pulmonary
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
The aim of the study is to assess safety, tolerability and clinical effects of different doses of riociguat in patients with inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and who are not satisfactorily treated…
- Trial name
- EAS (NCT01784562)
- Testing
- Adempas (Riociguat, BAY63-2521)
- Where
- 102 sites in United States, Austria and 18 more
- Sponsor
- Bayer
Pre-eclampsia, Preterm Birth
Maternal Serum Markers Predicting Preeclampsia At Early Gestations
This observational study aims to assess the effectiveness of a maternal blood test as a prognostic tool for predicting early pregnancy risk of preeclampsia (PE).
- Trial name
- NCT05131282
- Testing
- Blood test of PE risk, Blood test of Preterm PE risk
- Where
- 6 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- HBI Solutions Inc.
Type 2 Diabetes Mellitus, Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"
The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers
- Trial name
- NCT06226727
- Testing
- BR1019, BR1019-1, BR1019-2
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Normal Tension Glaucoma (NTG)
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
A randomized active-controlled multi-site double-masked 28 day study to evaluate the safety and tolerability of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with normal tension…
- Trial name
- NCT04857827
- Testing
- QLS-101, Timolol maleate PF 0.5% ophthalmic solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Qlaris Bio, Inc.
Hypertension, Dyslipidemias
To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults
This study is designated to evaluate the pharmacokinetic interactions of valsartan, amlodipine besylate, rosuvastatin, and ezetimibe in healthy male volunteers.
- Trial name
- NCT04185090
- Testing
- ID1803, ID1801, ID1803+ID1801
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.